Status and phase
Conditions
Treatments
About
A4368 is the autophagy activator that is being developed for the treatment of nonalcoholic steatohepatitis.
The goal of the study is to assess the safety, tolerability, and pharmacokinetics in healthy subjects.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
78 participants in 8 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal